Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
First Appeared on 2/14/2017
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|HPV4: HPV (GARDASIL) / MERCK & CO. INC.||- / -||UN / UN|
Administered by: Other Purchased by: Other
Symptoms: Epstein-Barr virus infection, Bedridden, Post viral fatigue syndrome
Life Threatening? No
Permanent Disability? Yes
ER or Doctor Visit? No
Other Medications: Baclofen; azithromycin; lansoprazole
Current Illness: Immunodeficiency common variable, variable immune deficiency; Immunisation
Diagnostic Lab Data:
CDC 'Split Type': WAES1610GBR015251
Write-up:Information was received from Sanofi Pasteur (manufacturer control # 2016010903) as part of a business agreement on 28-OCT-2016. This case was received from the RA on 26-OCT-2016 under the reference number GB-MHRA-ADR 23693153. Case received from a consumer/other non health professional. A 15-year-old female adolescent patient received GARDASIL, (batch number unknown) via parenteral route on 24-MAR-2014, GARDAIL, (batch number unknown) via parenteral route on 28-JUL-2014. The patient received concomitant administration of: -Baclofen on an unknown date, -Azithromycin on an unknown date, -Lansoprazole on an unknown date. The patient was firstly bed ridden after second was told this was unusual (onset date 24-MAR-2014). She also experienced Epstein-Barre virus infection and post viral fatigue syndrome on an unknown date. The patient had a medical history of immunodeficiency common variable. The patient''s outcome was reported as Not Recovered/Not Resolved.
Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166